Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > LATEST
LATEST
-
BUSINESS Will Unlisted AGs Rush for June Listing or Be Left on Ice?
January 23, 2026
-
REGULATORY Japan’s 1st Xolair Biosimilar Likely from Celltrion as JAN Is Assigned
January 23, 2026
-
REGULATORY DPP Vows to Scrap Off-Year Drug Price Revisions in Election Platform
January 23, 2026
-
REGULATORY Japan Starts Review on Scope of Drugs Eligible for Immunization Use, with Beyfortus in Focus
January 23, 2026
-
ORGANIZATION Off-Year Drug Price Revisions Run Counter to Innovation, JPMA Exec Says
January 23, 2026
-
BUSINESS Enhertu Reels in 6th China Indication in Second-Line Gastric Cancer
January 23, 2026
-
BUSINESS Maruho Out-Licenses Rapifort to Taiwan’s Orient EuroPharma
January 23, 2026
-
REGULATORY Takeda’s Miyabashira Urges National Strategy Act to Revive Japan as Innovation Powerhouse
January 22, 2026
-
REGULATORY LDP Pledges to Position Pharma as Core Industry in Campaign Platform
January 22, 2026
-
BUSINESS Towa to Take Over Manufacturing of Otsuka’s LLPs in Cross-Sector Tie-Up
January 22, 2026
-
REGULATORY Many Pharma-Savvy Lawmakers on LDP’s Candidate Roster for Lower House Poll
January 22, 2026
-
REGULATORY Japan Health Minister Says Early Call on FY2027 Off-Year Revision Improves Predictability
January 22, 2026
-
REGULATORY Japan Grants Sakigake Tag to Nanoscope’s MOGENRY
January 22, 2026
-
BUSINESS Otsuka/Ionis’ HAE Drug Dawnzera Approved in Europe
January 22, 2026
-
REGULATORY MHLW Official Making Rounds to Rally Private Support for Drug Discovery Fund
January 21, 2026
-
BUSINESS Shionogi to Lift Stake in ViiV to 21.7% as Pfizer Exits
January 21, 2026
-
ORGANIZATION Kobe, iPark Institute, Partners Sign Pact to Accelerate Innovation at KBIC
January 21, 2026
-
REGULATORY Cabinet OKs Subsidy to Boost Antibiotic API Stockpiles, Allocates 7.1 Billion Yen from Reserve
January 21, 2026
-
BUSINESS Fuji Pharma Earns Approval for High-Dose Stelara Biosimilar
January 21, 2026
-
REGULATORY PMDA Chief Vows Stronger Support for Drug Discovery, Orphan Designations
January 21, 2026
ページ
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…